These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7047618)

  • 1. Behavioral effects of carbidopa/levodopa in hyperactive boys.
    Langer DH; Rapoport JL; Brown GL; Ebert MH; Bunney WE
    J Am Acad Child Psychiatry; 1982 Jan; 21(1):10-8. PubMed ID: 7047618
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of levodopa on attention deficit disorder, residual type.
    Wood D; Reimherr F; Wender PH
    Psychiatry Res; 1982 Feb; 6(1):13-20. PubMed ID: 6949167
    [No Abstract]   [Full Text] [Related]  

  • 3. An open clinical trial of L-dopa and carbidopa in adults with minimal brain dysfunction.
    Reimherr FW; Wood DR; Wender PH
    Am J Psychiatry; 1980 Jan; 137(1):73-5. PubMed ID: 6986093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
    Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG
    Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

  • 6. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 7. Questioning a dopaminergic hypothesis.
    Langer DH; Rapoport JL; Brown GL; Ebert MH; Bunney WE
    Am J Psychiatry; 1981 Apr; 138(4):537-8. PubMed ID: 7011064
    [No Abstract]   [Full Text] [Related]  

  • 8. Parallel double-blind study of pergolide in Parkinson's disease.
    Jankovic J; Orman J
    Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
    Savery F
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
    [No Abstract]   [Full Text] [Related]  

  • 12. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of apomorphine and apomorphine-L-dopa-carbidopa on alcohol post-intoxication symptoms.
    Wadstein J; Ohlin H; Stenberg P
    Drug Alcohol Depend; 1978 Jul; 3(4):281-7. PubMed ID: 357128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
    Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Kask AM; Chase TN
    J Neurol Neurosurg Psychiatry; 1987 Feb; 50(2):194-8. PubMed ID: 3572434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
    Lieberman A; Goodgold A; Jonas S; Leibowitz M
    Neurology; 1975 Oct; 25(10):911-6. PubMed ID: 1101099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
    Goetz CG; Tanner CM; Shannon KM; Carroll VS; Klawans HL; Carvey PM; Gilley D
    Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
    Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
    Sage JI; Mark MH
    Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.